Address the challenges and limitations associated

The gap

Evidence profile

Stated in the future work and cells future research sections of the source papers, classified as general, spanning 2 journals.

Supporting evidence — 3 representative gaps

• GENE THERAPY: EMERGING TRENDS AND ITS TRANSFORMATIVE ROLE IN MODERN MEDICINE (2026) · Zenodo (CERN European Organization for Nuclear Research) · doi

  Advancements in genome editing, artificial intelligence, and nanotechnology are expected to further enhance gene therapy applications. The integration of these technologies may lead to more efficient, cost-effective, and widely accessible treatments in the future. 12. CONCLUSION Gene therapy represents a transformative approach in modern medicine by enabling targeted intervention at the genetic level. Although challenges such as safety, cost, and ethical considerations persist, continuous advancements in technology and regulatory frameworks are facilitating its clinical translation. With further research and innovation, gene therapy is expected to play a central role in the evolution of precision medicine and future healthcare systems. 13. REFERENCES 1. World Health Organization. Gene therapy overview. www.wjpr.net │ Vol 15, Issue 9, 2026. │ ISO 9001: 2015 Certified Journal │ 514 Taware. World Journal of Pharmaceutical Research 2. Doudna JA, Charpentier E. Genome editing with CRISPR-Cas9. Science., 2014. 3. Ginn SL, et al. Gene therapy clinical trials worldwide. J Gene Med., 2018. 4. Watson JD, Crick FH. Molecular structure of nucleic acids. Nature., 1953. 5. Anderson WF. Human gene therapy. Science, 1992. 6. Jinek M, et al. CRISPR-Cas9 system. Science, 2012. 7. Naldini L. Gene therapy returns to centre stage. Nature, 2015. 8. Wang D, et al. Viral vectors in gene therapy. Nat Rev Drug Discov., 2019. 9. Ramamoorth M, Narvekar A. Non-viral vectors. J Clin Diagn Res., 2015. 10. Dunbar CE, et al. Gene therapy applications. Science, 2018. 11. High KA, Roncarolo MG. Gene therapy benefits. N Engl J Med., 2019. 12. FDA. Gene therapy approvals report. 13. Ashley EA. Personalized medicine. Nat Rev Genet, 2016. 14. Hacein-Bey-Abina S, et al. Gene therapy risks. Science, 2003. 15. EMA/FDA guidelines on gene therapy. 16. National Institutes of Health. Future of gene therapy. www.wjpr.net │ Vol 15, Issue 9, 2026.

  generalstated in future workevidence 5/5
  Keywords: gene therapy science future medicine journal advancements genome editing expected further applications cost clinical world
• PRECISION THERAPEUTICS IN PRIMARY IMMUNE REGULATORY DISORDERS: CURRENT ADVANCES AND FUTURE DIRECTIONS (2026) · Zenodo (CERN European Organization for Nuclear Research) · doi

  Despite major progress in the knowledge and management of PIRDs, several problems persist. In order to enable prompt and reliable identification of affected patients, future research should concentrate on enhancing early diagnosis by the integration of nextgeneration sequencing, functional immunological assays, and new biomarkers.[1,3] A deeper comprehension of genotype-phenotype relationships will enhance disease prognostication and assist customized treatment plans. It is anticipated that as precision medicines continue to advance, PIRD therapy options will increase. Personalized combination therapy, pathway-specific small-molecule inhibitors, and emerging biologics may minimize the long-term toxicity of traditional immunosuppression while increasing efficacy. Furthermore, it is hoped that improvements in HSCT, such as better donor screening and optimal conditioning regimens, may increase survival and immune reconstitution in patients with severe illness.[3,4] Gene therapy and genome-editing techniques, especially those based on CRISPR-Cas9, present encouraging opportunities for fixing mutations that cause disease and attaining longterm remission or cure. These approaches are a significant step toward individualized therapy in PIRDs, even if they are still the subject of clinical research. Additionally, multicenter clinical trials, long-term follow-up studies, and international collaborative registries are crucial for bolstering the body of data, establishing uniform treatment guidelines, and enhancing patient outcomes globally.[3,4,5] Even with significant advancements in PIRD research and therapy, there are still a number of unanswered questions. In order to guarantee prompt and accurate diagnosis, the development new diagnostic of functional immunological testing, and novel biomarkers should be regarded as a crucial future trend (1,3). including next-generation sequencing, techniques www.wjpps.com │ Vol 15, Issue 8, 2026. │ ISO 9001: 2015 Certified Journal │ 625 Neeraja et al. World Journal of Pharmacy and Pharmaceutical Sciences A better understanding of genotype-phenotype connections will help determine the best course of treatment and prognosis. The creation of precision medicine will further increase the number of treatment opportunities for PIRDs patients. Biologics, inhibitors targeted at pathways and combinations of therapies will allow for more effective treatment and reduction of possible toxic effects of standard immunosuppressive therapy.

  generalstated in future workevidence 5/5
  Keywords: therapy treatment pirds patients increase long term techniques order prompt future enhancing diagnosis next generation
• CRISPR/Cas9 in cancer therapy: clinical translation, mechanistic strategies, and therapeutic directions (2026) · Frontiers in Oncology · doi

  Further studies are needed to address the challenges and limitations associated with the clinical application of CRISPR/Cas9. - The development of new technologies and strategies to improve the delivery and efficacy of CRISPR/Cas9 is necessary. - The integration of CRISPR/Cas9 with other therapeutic modalities may provide new treatment options for patients.

  generalstated in cells future researchevidence 5/5
  Keywords: further studies needed address challenges limitations associated clinical

Questions about this gap